Interferon beta-1a biosimilar high-dose (CinnaGen)

干扰素β-1a生物类似药 (high-dose,CinnaGen)

Report date: 2025/03/25 14:19:08

Base Information

Drug NameInterferon beta-1a biosimilar high-dose (CinnaGen)
Drug Alias Name干扰素β-1a生物仿制药 (CinnaGen)Rec Hu-IFN beta 1a-44 microgramReciGen
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCinnagen
China Registration ClassN/A

Develop Information

Active CompaniesCinnagen
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeL03AB07
Related LinksN/A